Fingolimod mitigates synaptic deficits and psychosis‐like behavior in APP/PSEN1 mice
Abstract Introduction Current treatments for psychosis in Alzheimer's disease (AD), a syndrome characterized by more rapid deterioration and reduced synaptic protein abundance relative to non‐psychotic AD, are inadequate. Fingolimod, a currently US Food and Drug Administration (FDA)–approved ph...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12324 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|